Intelligence · Clinical pipeline
Oncology · Phase II
Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.
Quick answer
Oncology Phase II programs: NovaPharmaNews indexes 2,637 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- First People's Hospital 261 programs
- Chinese Academy of 198 programs
- George Institute for 118 programs
- United Therapeutics Europe 112 programs
- Telethon Foundation 91 programs
- Takeda 79 programs
- Regeneron UK 71 programs
- MSD Merck Sharp 63 programs
- Ningbo Cancer Hospital 62 programs
- Anaxis Pharma 57 programs
- AstraZeneca 52 programs
- HOFFMANN-LA ROCHE 50 programs
Pipeline programs
-
CAAA601A32201
Advanced Accelerator Applications
somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas
1 trial -
CAAA601A42101
Novartis Pharmaceuticals
Extensive stage small cell lung cancer (ES-SCLC)
1 trial -
CAAA603D12101
Novartis Pharmaceuticals
Breast Cancer
1 trial -
CAAA614A12101
Novartis Pharmaceuticals
Recurrent or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Metastatic Breast Carcinoma (BC)
1 trial -
CAAA617A12202
Novartis Pharmaceuticals
Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) with moderate and severe renal impairment and with normal renal function.
1 trial -
CAAA617B12203
Novartis Pharmaceuticals
PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)
1 trial -
CAAA617H12101
Novartis Pharmaceuticals
Metastatic neuroendocrine prostate cancer
1 trial -
CAAA802A12101
Novartis Pharmaceuticals
PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and metastatic Castration-resistant Prostate Cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy.
1 trial -
CABL001E2201
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with imatinib and have not achieved deep molecular response
1 trial -
CABL001I12201
Novartis Pharmaceuticals
Pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors
1 trial -
CABL001L12101
Novartis Pharmaceuticals
relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)
1 trial -
CABOMETYX for bladder carcinoma of urothelial…
Fondazione Telethon ETS
bladder carcinoma of urothelial and non-urothelial histology
1 trial -
CABOZANTINIB
Fondazione Telethon ETS
Patients with metastatic clear cell renal cell carcinoma pretreated with immunocheckpoints inhibitors.
1 trial -
CABinMET
Fondazione Telethon ETS
Non small-cell lung cancer
1 trial -
CADILLACC TRIAL
Fondazione Telethon ETS
locally advanced cervical carcinoma
1 trial -
CAMN107AIT15
Novartis Pharmaceuticals
Chronic myeloid leukemia
1 trial -
CANNABIDIOL, DRONABINOL
Disc Medicine
Patients with untreatable hepatocellulare carcinoma
1 trial -
CAPECITABINE , OXALIPLATIN
Disc Medicine
Patients with early-stage rectal cancer (defined as early rectal cancer cT1-3abN0M0 or early-intermediate rectal cancer cT1-3abN1(≤3 nodes ≤8mm)M0
1 trial -
CAPECITABINE for Colon cancer
Fondazione Telethon ETS
Colon cancer
1 trial -
CAPTURE
Fondazione Telethon ETS
Patients with advanced oncologic disease receiving active treatment with WHO level II or III opioids and adjuvants therapies
1 trial -
CAR T-cell therapy
The First People's Hospital of Lianyungang
Acute Lymphoblastic Leukemia With Failed Remission
1 trial -
CAR-T
The First People's Hospital of Lianyungang
Leukemia, Lymphocytic, Chronic, B-Cell
1 trial -
CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance
Daihong Liu
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
1 trial -
CAR-T Cells
The First People's Hospital of Lianyungang
Lung Neoplasm Malignant
1 trial -
CART infusion
Hospital Authority, Hong Kong
B-cell Lymphoma Refractory
1 trial -
CART19-BE-02
The George Institute
Acute lymphoid leukemia
1 trial -
CAT-01
The George Institute
Cervical carcinoma
1 trial -
CBYL719X2402
Novartis Pharmaceuticals
Adult patients with PIK3CA mutant, HR-positive, HER2-negative advanced breast cancer
1 trial -
CC-486-NSCL-001
Celgene Europe Limited
Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)
1 trial -
CC-99282-NHL-001
Celgene Europe Limited
Follicular B-cell non-Hodgkin's lymphoma, Primary central nervous system lymphoma, Marginal zone lymphoma, Diffuse large B-cell lymphoma, Mantle cell lymphoma
1 trial -
CCRT with Maintenance Tislelizumab and Metronomic Capecitabine
BEONE MEDICINES AUS PTY LTD
Nasopharyngeal Carcinoma
1 trial -
CD123 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Leukemia
2 trials -
CD123 targeted CAR-NK cells
Chongqing Precision Biotech Co., Ltd
Acute Myeloid Leukemia
1 trial -
CD19 CAR T-Cell(CAT19T2)
Zhujiang Hospital
B-cell Acute Lymphoblastic Leukemia
1 trial -
CD19 CAR-T cells
The First People's Hospital of Lianyungang
Acute Lymphoblastic Leukemia
1 trial -
CD19 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Leukemia
2 trials -
CD19 CAR-T cells and CD19 positive feeder T cells
The First People's Hospital of Lianyungang
Acute Lymphoblastic Leukemia in Remission
1 trial -
CD19 and CD22 targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd
Leukemia, B-cell
2 trials -
CD19 and CD22 targeted prime CAR- T cells
Chongqing Precision Biotech Co., Ltd
B Cell Lymphoma
1 trial -
CD19 or CD20 CAR T cells briging HSCT
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lymphoma, Large B-Cell, Diffuse
1 trial -
CD19X CAR-T
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Large B-Cell Lymphoma (LBCL)
1 trial -
CD22/CD19 CAR T and auto-HSCT "sandwich" strategy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
B-cell Acute Lymphoblastic Leukemia
1 trial -
CDZR123A02101
Novartis Pharmaceuticals
advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, or other advanced/metastatic solid tumors, ovarian clear cell cancer, endometrial carcinoma, lymphoma including peripheral T-cell Lymphoma and GCBDLBCL, malignant pleural or peritoneal mesothelioma, metastatic castration - resistant prostate cancer (mCRPC))
1 trial -
CDZR123A12107
Novartis Pharmaceuticals
Metastatic castrate resistant prostate cancer (mCRPC)
1 trial -
CDZR123C12101
Novartis Pharmaceuticals
Metastatic hormone-sensitive prostate cancer
1 trial -
CEA CAR-T cells
Chongqing Precision Biotech Co., Ltd
Solid Tumor
1 trial -
CEA-targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd
Gastric Cancer
3 trials -
CECI830A12101
Novartis Pharmaceuticals
Advanced solid tumors, Advanced HR+/HER2- breast cancer
1 trial
Frequently asked questions
How many oncology Phase II programs exist?
2,637 programs match both the therapeutic area and stage filters in our published index.